OncoMatch/Clinical Trials/NCT06138990
Pharmacoscopy-guided Clinical Standard-of-care in r/r AML
Is NCT06138990 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Clinical standard-of-care (physician's choice) for aml, adult.
Treatment: Clinical standard-of-care (physician's choice) — With an overall survival of below 12 months, the outcome of relapsed/refractory AML (RR AML) is poor, making it a critical challenge to identify effective therapies at this stage. The RAPID-01 trial aims to show for the first time in a randomized and controlled clinical trial that Pharmacoscopy (PCY), a functional precision medicine platform, helps improve clinical standard-of-care treatment selection for patients suffering from relapsed/refractory AML.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Excluded: PML fusion with RARA
Acute promyelocytic leukemia (APL) with PML-RARA
Demographics
Prior therapy
Cannot have received: investigational drug
Participation in a clinical trial with an investigational drug within the 30 days preceding and during the present investigation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06138990 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational drug disqualifies patients from enrollment.
Are patients with PML alterations eligible?
No. PML fusion with RARA is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages